RBCC Gains New Funding Injection, Readies Aggressive Expansion Plan

HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCQB: RBCC) has received key new financing which will help propel the company’s aggressive growth plans in battling opioid and alcohol addiction, personalized medicine and 3D bioprinting.

“We’re ready to take a major step forward thanks to this important new funding”

“We’re ready to take a major step forward thanks to this important new funding,” said RBCC CEO Kimberly Palmer. “Events are moving quickly in Congress on the addiction front and we’ll now have the resources to respond with drug protocols and treatment options that can be an important part of the solution. We also can now pursue the opening of low-cost, inclusive opioid and alcohol treatment centers. Finally, we can continue to make advancements in 3D bioprinting, a field with tremendous promise. This is a big event and bodes well for our valued shareholders.”

RBCC stands poised to take advantage of several key trends in each of its primary areas of business.

First, the U.S. Congress is holding hearings on prescription drug abuse. Members have proposed several major bills offering solutions to stem the crisis of opioid addiction. An estimated 44 people per day die from overdosing on prescription painkillers.

In personalized medicine, one recent forecast has predicted the field will grow to a nearly $2.5 billion industry by 2022, a nearly 150 percent increase over its current size of $1 billion. In addition, more than one in four new drugs approved by the FDA last year were personalized medicine drugs.

Finally, according to some recent reports, bioprinting could become a $7 billion industry, which would mean bioprinting would make up half of the overall 3D printing market, itself a booming industry all its own.

For more information on RBCC’s initiatives, please visit www.rainbowbiocorp.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.rainbowbiocorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.